Relief Therapeutics Announces New Executive Leadership Team Strengthening Capabilities to Guide the Company through Pipeline Development Initiatives - Seite 2
All executive committee appointments are approved by the Board of Directors and effective immediately.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements
in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief's portfolio offers a balanced mix of marketed, revenue-generating
products, our proprietary, globally patented TEHCLO and Physiomimic platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core
therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. In addition, Relief is commercializing several legacy products via licensing and distribution
partners. Relief's mission is to provide therapeutic relief to those suffering from rare diseases and is being advanced by an international team of well-established, experienced biopharma industry
leaders with extensive research, development and rare disease expertise. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB
under the symbols RLFTF and RLFTY. For more information, please visit our website www.relieftherapeutics.com or follow Relief
on LinkedIn.
CONTACT :
RELIEF THERAPEUTICS Holding SA
Melinda Keegan
Melinda.keegan@relieftherapeutics.com
DISCLAIMER
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, including its ability to achieve its corporate, development and
commercial goals, and other factors which could cause the actual results, financial condition, performance, or achievements of Relief to be materially different from any future results, performance
or achievements expressed or implied by such forward-looking statements. A number of factors, including those described in Relief's filings with the SIX Swiss Exchange and the U.S. Securities and
Exchange Commission (SEC), could adversely affect Relief. Copies of Relief's filings with the SEC are available on the SEC EDGAR database at www.sec.gov. Relief does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Lesen Sie auch
SOURCE: Relief Therapeutics Holdings AG
View the original press release on accesswire.com
The RELIEF THERAPEUTICS Stock at the time of publication of the news with a raise of +211,48 % to 0,010EUR on Lang & Schwarz stock exchange (11. Mai 2018, 10:40 Uhr).